Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia.
D'Arena G, D'Auria F, Simeon V, Laurenti L, Deaglio S, Mansueto G, Del Principe MI, Statuto T, Pietrantuono G, Guariglia R, Innocenti I, Martorelli MC, Villani O, De Feo V, Del Poeta G, Musto P. D'Arena G, et al. Among authors: simeon v. Am J Hematol. 2012 Jun;87(6):628-31. doi: 10.1002/ajh.23170. Epub 2012 Mar 28. Am J Hematol. 2012. PMID: 22460620 Free article.
Regulatory T-cells in chronic lymphocytic leukemia and autoimmune diseases.
D'Arena G, Rossi G, Vannata B, Deaglio S, Mansueto G, D'Auria F, Statuto T, Simeon V, De Martino L, Marandino A, Del Poeta8 G, De Feo V, Musto P. D'Arena G, et al. Among authors: simeon v. Mediterr J Hematol Infect Dis. 2012;4(1):e2012053. doi: 10.4084/MJHID.2012.053. Epub 2012 Aug 9. Mediterr J Hematol Infect Dis. 2012. PMID: 22973497 Free PMC article.
Regulatory T-cell modulation by green tea in chronic lymphocytic leukemia.
D'Arena G, Simeon V, De Martino L, Statuto T, D'Auria F, Volpe S, Deaglio S, Maidecchi A, Mattoli L, Mercati V, Musto P, De Feo V. D'Arena G, et al. Among authors: simeon v. Int J Immunopathol Pharmacol. 2013 Jan-Mar;26(1):117-25. doi: 10.1177/039463201302600111. Int J Immunopathol Pharmacol. 2013. PMID: 23527714 Free article. Clinical Trial.
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.
Musto P, Simeon V, Martorelli MC, Petrucci MT, Cascavilla N, Di Raimondo F, Caravita T, Morabito F, Offidani M, Olivieri A, Benevolo G, Mina R, Guariglia R, D'Arena G, Mansueto G, Filardi N, Nobile F, Levi A, Falcone A, Cavalli M, Pietrantuono G, Villani O, Bringhen S, Omedè P, Lerose R, Agnelli L, Todoerti K, Neri A, Boccadoro M, Palumbo A. Musto P, et al. Among authors: simeon v. Leukemia. 2014 Jan;28(1):222-5. doi: 10.1038/leu.2013.241. Epub 2013 Aug 20. Leukemia. 2014. PMID: 23958922 No abstract available.
Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy.
Musto P, Simeon V, Guariglia R, Bianchino G, Grieco V, Nozza F, La Rocca F, Marziano G, Lalinga AV, Fabiani E, Voso MT, Scaravaglio P, Mecucci C, D'Arena G. Musto P, et al. Among authors: simeon v. Onco Targets Ther. 2014 Jun 13;7:1043-50. doi: 10.2147/OTT.S59628. eCollection 2014. Onco Targets Ther. 2014. PMID: 24966686 Free PMC article. Review.
171 results